Ubs Group Ag Addex Therapeutics Ltd. Transaction History

Ubs Group Ag

11 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2023 Nov 09, 2023	BUY	$0.34 - $0.62 $25 - $45	74 New	74 $0
Q4 2022 Feb 08, 2023	BUY	$0.55 - $18.0 $4,121 - $134,874	7,493 Added 106.54%	14,526 $9,000
Q3 2022 Nov 10, 2022	SELL	$0.78 - $16.4 $718 - $15,104	-921 Reduced 11.58%	7,033 $6,000
Q2 2022 Aug 10, 2022	BUY	$1.05 - $5.35 $5,405 - $27,541	5,148 Added 183.46%	7,954 $9,000
Q1 2022 May 16, 2022	SELL	$4.27 - $6.83 $61,889 - $98,994	-14,494 Reduced 83.78%	2,806 $14,000
Q4 2021 Feb 14, 2022	BUY	$6.29 - $9.4 $27,047 - $40,420	4,300 Added 33.08%	17,300 $109,000
Q3 2021 Nov 15, 2021	BUY	$9.0 - $10.9 $2,565 - $3,106	285 Added 2.24%	13,000 $117,000
Q2 2021 Aug 13, 2021	BUY	$8.91 - $11.25 $90,837 - $114,693	10,195 Added 404.56%	12,715 $122,000
Q1 2021 May 12, 2021	BUY	$9.82 - $14.11 $23,764 - $34,146	2,420 Added 2420.0%	2,520 $26,000
Q4 2020 Feb 11, 2021	SELL	$9.79 - $24.19 $10,220 - $25,254	-1,044 Reduced 91.26%	100 $1,000
Q3 2020 Nov 12, 2020	BUY	$7.0 - $21.0 $8,008 - $24,024	1,144 New	1,144 $14,000

Ticker ADXN
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 8,204,630
Market Cap $65.6M
Description
Addex Therapeutics Ltd, a development-stage biopharmaceutical company, discovers, develops, and commercializes small-molecule pharmaceutical products for central nervous system (CNS) disorders in Switzerland. The company focuses on the discovery of oral small molecule allosteric modulators of G-protein coupled receptors. Its lead programs includ...

Get notified when there are updates to the investment portfolio of Ubs Group Ag, based on Form 13F filings with the SEC.

Stay updated on Ubs Group Ag with notifications on news.